Related references
Note: Only part of the references are listed.Pulmonary Exacerbations in Adults With Cystic Fibrosis A Grown-up Issue in a Changing Cystic Fibrosis Landscape
Gemma E. Stanford et al.
CHEST (2021)
Long-term safety study of colistimethate sodium (Colobreathe?): Findings from the UK Cystic Fibrosis Registry
Sigal Kaplan et al.
JOURNAL OF CYSTIC FIBROSIS (2021)
Development of elexacaftor - tezacaftor - ivacaftor: Highly effective CFTR modulation for the majority of people with Cystic Fibrosis
Peter G. Middleton et al.
EXPERT REVIEW OF RESPIRATORY MEDICINE (2021)
It's Not Easy Being Green: A Narrative Review on the Microbiology, Virulence and Therapeutic Prospects of Multidrug-Resistant Pseudomonas aeruginosa
Payam Behzadi et al.
ANTIBIOTICS-BASEL (2021)
Amikacin liposome inhalation suspension for chronic Pseudomonas aeruginosa infection in cystic fibrosis
Diana Bilton et al.
JOURNAL OF CYSTIC FIBROSIS (2020)
Changing epidemiology of the respiratory bacteriology of patients with cystic fibrosis-data from the European cystic fibrosis society patient registry
Elpis Hatziagorou et al.
JOURNAL OF CYSTIC FIBROSIS (2020)
Antimicrobial resistance in cystic fibrosis: A Delphi approach to defining best practices
Edith Zemanick et al.
JOURNAL OF CYSTIC FIBROSIS (2020)
Tezacaftor and ivacaftor for the treatment of cystic fibrosis
Sarah L. Paterson et al.
EXPERT REVIEW OF RESPIRATORY MEDICINE (2020)
Cystic fibrosis - Ten promising therapeutic approaches in the current era of care
Ranjani Somayaji et al.
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2020)
Untargeted Metagenomic Investigation of the Airway Microbiome of Cystic Fibrosis Patients with Moderate-Severe Lung Disease
Giovanni Bacci et al.
MICROORGANISMS (2020)
P150 Aztreonam lysine recovers lung function and improves quality of life in the treatment of acute exacerbations of cystic fibrosis: results from an open-label randomised crossover study (AZTEC-CF)
F. Frost et al.
Journal of Cystic Fibrosis (2020)
Intravenous versus oral antibiotics for eradication of Pseudomonas aeruginosa in cystic fibrosis (TORPEDO-CF): a randomised controlled trial
Simon C Langton Hewer et al.
Lancet Respiratory Medicine (2020)
Association of Inhaled Antibiotics in Addition to Standard Intravenous Therapy and Outcomes of Pediatric Inpatient Pulmonary Exacerbations
Jonathan D. Cogen et al.
ANNALS OF THE AMERICAN THORACIC SOCIETY (2020)
Eradication of early P-aeruginosa infection in children <7 years of age with cystic fibrosis: The early study
Felix Ratjen et al.
JOURNAL OF CYSTIC FIBROSIS (2019)
Eradication of persistent methicillin-resistant Staphylococcus aureus infection in cystic fibrosis
Rebecca Dezube et al.
JOURNAL OF CYSTIC FIBROSIS (2019)
The effects of cycled inhaled aztreonam on the cystic fibrosis (CF) lung microbiome
Alya A. Heirali et al.
JOURNAL OF CYSTIC FIBROSIS (2019)
Methicillin-resistant Staphylococcus aureus eradication in cystic fibrosis patients: A randomized multicenter study
Daniela Dolce et al.
PLOS ONE (2019)
Anti-pseudomonad Activity of Manuka Honey and Antibiotics in a Specialized ex vivo Model Simulating Cystic Fibrosis Lung Infection
Aled E. L. Roberts et al.
FRONTIERS IN MICROBIOLOGY (2019)
Tolerance and Resistance of Pseudomonas aeruginosa Biofilms to Antimicrobial Agents-How P. aeruginosa Can Escape Antibiotics
Oana Ciofu et al.
FRONTIERS IN MICROBIOLOGY (2019)
Deciphering the Ecology of Cystic Fibrosis Bacterial Communities: Towards Systems-Level Integration
Annamaria Bevivino et al.
TRENDS IN MOLECULAR MEDICINE (2019)
Antimicrobial Treatment of Staphylococcus aureus in Patients With Cystic Fibrosis
Susanna Esposito et al.
FRONTIERS IN PHARMACOLOGY (2019)
Acute Pulmonary Exacerbations in Cystic Fibrosis
Christopher H. Goss
SEMINARS IN RESPIRATORY AND CRITICAL CARE MEDICINE (2019)
Nebulized gentamicin in combination with systemic antibiotics for eradicating early Pseudomonas aeruginosa infection in children with cystic fibrosis
Ben Van Stormbroek et al.
PEDIATRIC PULMONOLOGY (2019)
Developing Inhaled Antibiotics in Cystic Fibrosis: Current Challenges and Opportunities
Dave P. Nichols et al.
ANNALS OF THE AMERICAN THORACIC SOCIETY (2019)
Prevalence and Antibiotic Resistance of Stenotrophomonas maltophilia in Respiratory Tract Samples: A 10-Year Epidemiological Snapshot
Mario Gajdacs et al.
HEALTH SERVICES RESEARCH AND MANAGERIAL EPIDEMIOLOGY (2019)
The Continuing Threat of Methicillin-Resistant Staphylococcus aureus
Mario Gajdacs
ANTIBIOTICS-BASEL (2019)
Eradication therapy for Burkholderia cepacia complex in people with cystic fibrosis
Kate H. Regan et al.
COCHRANE DATABASE OF SYSTEMATIC REVIEWS (2019)
Azithromycin for Early Pseudomonas Infection in Cystic Fibrosis The OPTIMIZE Randomized Trial
Nicole Mayer-Hamblett et al.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2018)
Human airway mucus alters susceptibility of Pseudomonas aeruginosa biofilms to tobramycin, but not colistin
Laura Mueller et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2018)
ECFS best practice guidelines: the 2018 revision
Carlo Castellani et al.
JOURNAL OF CYSTIC FIBROSIS (2018)
PEGylation of Tobramycin Improves Mucus Penetration and Antimicrobial Activity against Pseudomonas aeruginosa Biofilms in Vitro
Tania F. Bahamondez-Canas et al.
MOLECULAR PHARMACEUTICS (2018)
Fluctuations in airway bacterial communities associated with clinical states and disease stages in cystic fibrosis
Lisa A. Carmody et al.
PLOS ONE (2018)
Successful eradication of newly acquired MRSA in six of seven patients with cystic fibrosis applying a short-term local and systemic antibiotic scheme
Alexander Kiefer et al.
BMC PULMONARY MEDICINE (2018)
Implementation of a successful eradication protocol for Burkholderia Cepacia complex in cystic fibrosis patients
Bryan A. Garcia et al.
BMC PULMONARY MEDICINE (2018)
Staphylococcus aureus in cystic fibrosis: pivotal role or bit part actor?
Matthew N. Hurley et al.
CURRENT OPINION IN PULMONARY MEDICINE (2018)
New anti-pseudomonal agents for cystic fibrosis- still needed in the era of small molecule CFTR modulators?
Jane C. Davies et al.
EXPERT OPINION ON PHARMACOTHERAPY (2018)
Microbiological efficacy of early MRSA treatment in cystic fibrosis in a randomised controlled trial
Marianne Sponer Muhlebach et al.
THORAX (2017)
Impact of azithromycin on the clinical and antimicrobial effectiveness of tobramycin in the treatment of cystic fibrosis
Dave P. Nichols et al.
JOURNAL OF CYSTIC FIBROSIS (2017)
Effectiveness of a stepwise Pseudomonas aeruginosa eradication protocol in children with cystic fibrosis
Ana C. Blanchard et al.
JOURNAL OF CYSTIC FIBROSIS (2017)
Use of FEV1 in cystic fibrosis epidemiologic studies and clinical trials: A statistical perspective for the clinical researcher
Rhonda Szczesniak et al.
JOURNAL OF CYSTIC FIBROSIS (2017)
The fate of inhaled antibiotics after deposition in cystic fibrosis: How to get drug to the bug?
Aukje C. Bos et al.
JOURNAL OF CYSTIC FIBROSIS (2017)
Tobramycin inhalation powder for the treatment of pulmonary Pseudomonas aeruginosa infection in patients with cystic fibrosis: a review based on clinical evidence
Kamal Hamed et al.
THERAPEUTIC ADVANCES IN RESPIRATORY DISEASE (2017)
The effects of inhaled aztreonam on the cystic fibrosis lung microbiome
Alya A. Heirali et al.
MICROBIOME (2017)
Staphylococcus aureus interaction with Pseudomonas aeruginosa biofilm enhances tobramycin resistance
T. Beaudoin et al.
NPJ BIOFILMS AND MICROBIOMES (2017)
Antibiotic strategies for eradicating Pseudomonas aeruginosa in people with cystic fibrosis
Simon C. Langton Hewer et al.
COCHRANE DATABASE OF SYSTEMATIC REVIEWS (2017)
New Inhaled Antimicrobial Formulations for Use in the Cystic Fibrosis Patient Population
Christopher T. Campbell et al.
ANNALS OF PHARMACOTHERAPY (2016)
Sequential Treatment of Biofilms with Aztreonam and Tobramycin Is a Novel Strategy for Combating Pseudomonas aeruginosa Chronic Respiratory Infections
Estrella Rojo-Molinero et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2016)
Comparison of Inhaled Antibiotics for the Treatment of Chronic Pseudomonas aeruginosa Lung Infection in Patients With Cystic Fibrosis: Systematic Literature Review and Network Meta-analysis
J. Stuart Elborn et al.
CLINICAL THERAPEUTICS (2016)
The Microbiome in Cystic Fibrosis
Yvonne J. Huang et al.
CLINICS IN CHEST MEDICINE (2016)
Production of extended-spectrum β-lactamases and the potential indirect pathogenic role of Prevotella isolates from the cystic fibrosis respiratory microbiota
Laura J. Sherrard et al.
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS (2016)
Continuous alternating inhaled antibiotics for chronic pseudomonal infection in cystic fibrosis
Patrick A. Flume et al.
JOURNAL OF CYSTIC FIBROSIS (2016)
Improving inhaled antibiotic treatment - Practice defeats the proof
C. Kors van der Ent et al.
JOURNAL OF CYSTIC FIBROSIS (2016)
Continuous alternating inhaled antibiotic therapy in CF: A single center retrospective analysis
C. Van de Kerkhove et al.
JOURNAL OF CYSTIC FIBROSIS (2016)
Safety and efficacy of prolonged levofloxacin inhalation solution (APT-1026) treatment for cystic fibrosis and chronic Pseudomonas aeruginosa airway infection
J. Stuart Elborn et al.
JOURNAL OF CYSTIC FIBROSIS (2016)
Eradication failure of newly acquired Pseudomonas aeruginosa isolates in cystic fibrosis
Malena Cohen-Cymberknoh et al.
JOURNAL OF CYSTIC FIBROSIS (2016)
A phase 3, multi-center, multinational, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of levofloxacin inhalation solution (APT-1026) in stable cystic fibrosis patients
Patrick A. Flume et al.
JOURNAL OF CYSTIC FIBROSIS (2016)
Eradication of methicillin resistant Staphylococcus aureus detected for the first time in cystic fibrosis: A single center observational study
Matthias Kappler et al.
PEDIATRIC PULMONOLOGY (2016)
Respiratory syncytial virus infection enhances Pseudomonas aeruginosa biofilm growth through dysregulation of nutritional immunity
Matthew R. Hendricks et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2016)
Inhaled antibiotics for the treatment of chronic Pseudomonas aeruginosa infection in cystic fibrosis patients: challenges to treatment adherence and strategies to improve outcomes
Reka Bodnar et al.
PATIENT PREFERENCE AND ADHERENCE (2016)
Mucin Binding Reduces Colistin Antimicrobial Activity
Johnny X. Huang et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2015)
Novel inhaled combined antibiotic formulations in the treatment of Pseudomonas aeruginosa airways infections in cystic fibrosis
Sabina Antoniu
EXPERT REVIEW OF ANTI-INFECTIVE THERAPY (2015)
Antimicrobial efficacy of tobramycin polymeric nanoparticles for Pseudomonas aeruginosa infections in cystic fibrosis: Formulation, characterisation and functionalisation with dornase alfa (DNase)
Jill Deacon et al.
JOURNAL OF CONTROLLED RELEASE (2015)
Association between the introduction of a new cystic fibrosis inhaled antibiotic class and change in prevalence of patients receiving multiple inhaled antibiotic classes
Elliott C. Dasenbrook et al.
JOURNAL OF CYSTIC FIBROSIS (2015)
A phase 3, open-label, randomized trial to evaluate the safety and efficacy of levofloxacin inhalation solution (APT-1026) versus tobramycin inhalation solution in stable cystic fibrosis patients
J. Stuart Elbom et al.
JOURNAL OF CYSTIC FIBROSIS (2015)
The daily dynamics of cystic fibrosis airway microbiota during clinical stability and at exacerbation
Lisa A. Carmody et al.
MICROBIOME (2015)
Interventions for the eradication of meticillin-resistant Staphylococcus aureus (MRSA) in people with cystic fibrosis
David K. H. Lo et al.
COCHRANE DATABASE OF SYSTEMATIC REVIEWS (2015)
Pulmonary Exacerbations in Children with Cystic Fibrosis
Valerie Waters et al.
ANNALS OF THE AMERICAN THORACIC SOCIETY (2015)
Longevity of Patients With Cystic Fibrosis in 2000 to 2010 and Beyond: Survival Analysis of the Cystic Fibrosis Foundation Patient Registry
Todd MacKenzie et al.
ANNALS OF INTERNAL MEDICINE (2014)
Pyrosequencing reveals transient cystic fibrosis lung microbiome changes with intravenous antibiotics
Daniel J. Smith et al.
EUROPEAN RESPIRATORY JOURNAL (2014)
Mechanisms of reduced susceptibility and genotypic prediction of antibiotic resistance in Prevotella isolated from cystic fibrosis (CF) and non-CF patients
Laura J. Sherrard et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2014)
Inhaled aztreonam for chronic Burkholderia infection in cystic fibrosis: A placebo-controlled trial
D. Elizabeth Tullis et al.
JOURNAL OF CYSTIC FIBROSIS (2014)
Antimicrobial resistance in the respiratory microbiota of people with cystic fibrosis
Laura J. Sherrard et al.
LANCET (2014)
Eradication therapy for Pseudomonas aeruginosa colonization episodes in cystic fibrosis patients not chronically colonized by P. aeruginosa
Petra Schelstraete et al.
JOURNAL OF CYSTIC FIBROSIS (2013)
Inhaled aztreonam lysine vs. inhaled tobramycin in cystic fibrosis: A comparative efficacy trial
Baroukh M. Assael et al.
JOURNAL OF CYSTIC FIBROSIS (2013)
Early treatment with inhaled antibiotics postpones next occurrence of Achromobacter in cystic fibrosis
M. Wang et al.
JOURNAL OF CYSTIC FIBROSIS (2013)
Safety, efficacy and convenience of colistimethate sodium dry powder for inhalation (Colobreathe DPI) in patients with cystic fibrosis: a randomised study
Antje Schuster et al.
THORAX (2013)
Treatment of pulmonary exacerbations in cystic fibrosis
Jayesh M. Bhatt
EUROPEAN RESPIRATORY REVIEW (2013)
Treatment of lung infection in patients with cystic fibrosis: Current and future strategies
Gerd Doering et al.
JOURNAL OF CYSTIC FIBROSIS (2012)
Managing Cystic Fibrosis Strategies That Increase Life Expectancy and Improve Quality of Life
Malena Cohen-Cymberknoh et al.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2011)
Pharmacokinetics and Safety of MP-376 (Levofloxacin Inhalation Solution) in Cystic Fibrosis Subjects
David E. Geller et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2011)
Comparative Efficacy and Safety of 4 Randomized Regimens to Treat Early Pseudomonas aeruginosa Infection in Children With Cystic Fibrosis
Miriam M. Treggiari et al.
ARCHIVES OF PEDIATRICS & ADOLESCENT MEDICINE (2011)
Update on methicillin-resistant Staphylococcus aureus in cystic fibrosis
Elliott C. Dasenbrook
CURRENT OPINION IN PULMONARY MEDICINE (2011)
Safety, efficacy and convenience of tobramycin inhalation powder in cystic fibrosis patients: The EAGER trial
Michael W. Konstan et al.
JOURNAL OF CYSTIC FIBROSIS (2011)
Marked increase in incidence of Achromobacter xylosoxidans infections caused by sporadic acquisition from the environment
Winnie Ridderberg et al.
JOURNAL OF CYSTIC FIBROSIS (2011)
Aztreonam for inhalation solution (AZLI) in patients with cystic fibrosis, mild lung impairment, and P. aeruginosa
C. E. Wainwright et al.
JOURNAL OF CYSTIC FIBROSIS (2011)
Tobramycin Inhalation Powder for P. aeruginosa Infection in Cystic Fibrosis: The EVOLVE Trial
Michael W. Konstan et al.
PEDIATRIC PULMONOLOGY (2011)
In Vitro Pharmacodynamics of Levofloxacin and Other Aerosolized Antibiotics under Multiple Conditions Relevant to Chronic Pulmonary Infection in Cystic Fibrosis
Paula King et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2010)
Association Between Respiratory Tract Methicillin-Resistant Staphylococcus aureus and Survival in Cystic Fibrosis
Elliott C. Dasenbrook et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2010)
An 18-Month Study of the Safety and Efficacy of Repeated Courses of Inhaled Aztreonam Lysine in Cystic Fibrosis
Christopher M. Oermann et al.
PEDIATRIC PULMONOLOGY (2010)
Treatment of early Pseudomonas aeruginosa infection in patients with cystic fibrosis: the ELITE trial
Felix Ratjen et al.
THORAX (2010)
Aztreonam lysine: a novel inhalational antibiotic for cystic fibrosis
Michael D Parkins et al.
Expert Review of Respiratory Medicine (2010)
Cystic Fibrosis Pulmonary Guidelines Treatment of Pulmonary Exacerbations
Patrick A. Flume et al.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2009)
Efficacy and Safety of Inhaled Aztreonam Lysine for Airway Pseudomonas in Cystic Fibrosis
George Z. Retsch-Bogart et al.
CHEST (2009)
Prevalence and Impact of Respiratory Viral Infections in Young Children With Cystic Fibrosis: Prospective Cohort Study
Bart E. van Ewijk et al.
PEDIATRICS (2008)
Aerosolized antibiotics in cystic fibrosis: current and future trends
Stanley B Fiel
Expert Review of Respiratory Medicine (2008)
Compounded colistimethate as possible cause of fatal acute respiratory distress syndrome
Karen S. McCoy
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Successful decolonization of meticillin-resistant Staphylococcus aureus in paediatric patients with cystic fibrosis (CF) using a three-step protocol
M. Macfarlane et al.
JOURNAL OF HOSPITAL INFECTION (2007)
Treatment of early Pseudomonas aeruginosa infection in patients with cystic fibrosis
Felix Ratjen
CURRENT OPINION IN PULMONARY MEDICINE (2006)
Early eradication therapy against Pseudomonas aeruginosa in cystic fibrosis patients
G Taccetti et al.
EUROPEAN RESPIRATORY JOURNAL (2005)
Azithromycin retards Pseudomonas aeruginosa Biofilm Formation
RJ Gillis et al.
JOURNAL OF CLINICAL MICROBIOLOGY (2004)
Azithromycin for cystic fibrosis
KW Southern et al.
EUROPEAN RESPIRATORY JOURNAL (2004)
Treatment with tobramycin solution for inhalation reduces hospitalizations in young CF subjects with mild lung disease
TD Murphy et al.
PEDIATRIC PULMONOLOGY (2004)
Methicillin-resistant Staphylococcus aureus in children with cystic fibrosis:: An eradication protocol
A Solís et al.
PEDIATRIC PULMONOLOGY (2003)
Significant microbiological effect of inhaled tobramycin in young children with cystic fibrosis
RL Gibson et al.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2003)
A randomised clinical trial of nebulised tobramycin or colistin in cystic fibrosis
ME Hodson et al.
EUROPEAN RESPIRATORY JOURNAL (2002)
Long-term benefits of inhaled tobramycin in adolescent patients with cystic fibrosis
RB Moss
CHEST (2002)
A ten year review of Colomycin
JM Littlewood et al.
RESPIRATORY MEDICINE (2000)
Share Paper
